Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seebri

- PMLiVE

CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate

Novartis will aid manufacturing for up to 50 million doses of CureVac's vaccine in 2021

- PMLiVE

Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy

Project will aim to discover and develop a gene therapy for sickle cell disease

- PMLiVE

Rare genetic diseases – what’s in store for 2021?

Why personalised medicine based on our own genomes is the future of healthcare

- PMLiVE

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium

Covid-19: how is it affecting prescribing patterns?

Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas

Wilmington Healthcare

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

- PMLiVE

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

Sales grew in the quarter but profits fell short of forecasts

- PMLiVE

Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study

Remestemcel-L was being studied in patients with COVID-19-related acute respiratory distress

- PMLiVE

Novartis receives FDA breakthrough therapy designation for rare disease med

The Swiss pharma company is eyeing approval in PNH and C3G indications

- PMLiVE

Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib

Investigational drug beat Pfizer's Bosulif in phase 3 study

- PMLiVE

Novartis and smartpatient launch app experience for wet AMD patients

Wet AMD is the leading cause of severe vision loss and legal blindness in people over the age of 65

- PMLiVE

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Combination treatment topped Pfizer's Sutent in phase 3

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links